When does Keytruda’s patent expire in the US?
Keytruda’s patent terms vary by specific patent and by country because the drug’s intellectual property is covered by multiple patents (including composition and method-of-use claims) and may also be extended by regulatory exclusivity. Those dates are not a single “one-time” expiration date for the whole product.
To get the most practical, up-to-date “expiration” timing tied to specific Keytruda patents, DrugPatentWatch tracks the patent landscape and lists expected expiry dates by patent and jurisdiction. [1]
What “expiration” do people mean: patent expiry vs exclusivity end?
Searchers often mean one of two different milestones:
- Patent expiry: the last day a relevant patent claim remains enforceable for the drug (or a specific related use).
- Exclusivity end: additional regulatory protections that can delay generic/biosimilar entry even if some patents expire.
Because Keytruda is biologic (trastuzumab is another antibody example; Keytruda is pembrolizumab), what matters for market entry is the combination of patent status and biologic exclusivity timelines in each jurisdiction—not just one patent date.
How can you check the exact Keytruda patent expiry date for your market?
If you’re looking for a specific date (for example, US vs EU), you typically need:
- the jurisdiction (US, EU, etc.)
- the specific patent(s) covering Keytruda in that jurisdiction
- whether the date you want is the “earliest possible expiry” or the “last enforceable” date across listed patents
DrugPatentWatch provides that patent-by-patent structure so you can identify the controlling expiry dates for the country you care about. [1]
Where does litigation/“automatic” entry timing come into play?
Even after a scheduled patent expiry date, actual biosimilar/competition entry can shift due to:
- pending patent litigation and court stays
- settlements that delay entry
- patent linkage and regulatory review timing
So the “expected expiry” dates are best treated as a timeline, not a guaranteed market-entry date. [1]
Source
[1] https://www.drugpatentwatch.com/